Update: Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study

(Updates to reflect stock price movement in the headline and first paragraph.) Alnylam Pharmaceuticals (ALNY) shares were up more than 6% in recent Tuesday trading, a day after the company said vutris

MT NewswiresJun 26 01:17

Alnylam Pharmaceuticals(ALNY.US) Director Sells US$7.16 Million in Common Stock

$Alnylam Pharmaceuticals(ALNY.US)$ Director PYOTT DAVID E I sold 32,450 shares of common stock on Jun 24, 2024 at an average price of $221 for a total value of $7.16 million.Source: Announcement What

Futu News05:12

Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing

David E I Pyott, Director, on June 24, 2024, sold 32,450 shares in Alnylam Pharmaceuticals (ALNY) for $7,161,360. Following the Form 4 filing with the SEC, Pyott has control over a total of 28,036 sha

MT Newswires04:32

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

Benzinga01:35

Alnylam Pharmaceuticals on Track for Record High Close -- Data Talk

Alnylam Pharmaceuticals, Inc (ALNY) is currently at $245.68, up $5.53 or 2.3% --Would be new all-time high (Based on available data back to May 28, 2004) --Would be the first record close since Dec.

Dow Jones00:22

A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $234 to $291

On Jun 26, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $234 to $291.Morgan Stanley analyst Michael Ulz maintains with a hold

Futu NewsJun 26 21:00 · Ratings